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Abstract
On analyzing the results of cell-based assays, we have previously shown that perilla (Perilla frutescens) leaf extract
(PLE), a food supplement and orally deliverable traditional Chinese medicine approved by the Taiwan Food and Drug
Administration, effectively inhibits SARS-CoV-2 by directly targeting virions. PLE was also found to modulate virusinduced cytokine expression levels. In this study, we explored the anti-SARS-CoV-2 activity of PLE in a hamster model
by examining viral loads and virus-induced immunopathology in lung tissues. Experimental animals were intranasally
challenged with different SARS-CoV-2 doses. Jugular blood samples and lung tissue specimens were obtained in the
acute disease stage (3e4 post-infection days). As expected, SARS-CoV-2 induced lung inﬂammation and hemorrhagic
effusions in the alveoli and perivascular areas; additionally, it increased the expression of several immune markers of
lung injury ¡ including lung Ki67-positive cells, Iba-1-positive macrophages, and myeloperoxidase-positive neutrophils. Virus-induced lung alterations were signiﬁcantly attenuated by orally administered PLE. In addition, pretreatment
of hamsters with PLE signiﬁcantly reduced viral loads and immune marker expression. A puriﬁed active fraction of PLE
was found to confer higher antiviral protection. Notably, PLE prevented SARS-CoV-2-induced increase in serum
markers of liver and kidney function as well as the decrease in serum high-density lipoprotein and total cholesterol
levels in a dose-dependent fashion. Differently from lung pathology, monitoring of serum biomarkers in Syrian
hamsters may allow a more humane assessment of the novel drugs with potential anti-SARS-CoV-2 activity. Our results
expand prior research by conﬁrming that PLE may exert an in vivo therapeutic activity against SARS-CoV-2 by attenuating viral loads and lung tissue inﬂammation, which may pave the way for future clinical applications.
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1. Introduction
hile ﬁrst-generation vaccines are generally
sufﬁcient to elicit a robust immunological
response against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), a subgroup of
fully vaccinated individuals remains at risk of
breakthrough infections during different waves of
the pandemic driven by novel variants of concern.
SARS-CoV-2 enters human cells by utilizing the
angiotensin-converting enzyme 2 (ACE2) receptor
expressed in various tissues (e.g., lung, heart, kidney, gastrointestinal tract, and liver). Additionally,
elevated serum concentrations of proinﬂammatory
molecules are hallmarks of the cytokine storm
occurring in severe Coronavirus Disease 2019
(COVID-19) [1]. A clinical trial has shown that the
viral polymerase inhibitor remdesivir may shorten
the duration of hospital stay in patients with mild
disease [2]. Another study indicated that the viral
3C-like inhibitor PF-07321332 in combination with
ritonavir (commercial name: Paxlovid) may reduce
hospitalizations by 89% when given in the ﬁrst few
days after disease inception [3]. However, the
appearance of novel variants of concerns and the
adverse effects of ritonavir have prompted intense
research on other antiviral compounds with novel
mechanisms of action to tackle new pandemic
waves in countries characterized by vaccine
shortage. In the quest to address this unmet medical
need, animal models can be useful to predict the
effectiveness of novel antiviral compounds before
their progression to clinical trials. While murine
models have been largely popular in antiviral
research, mice are not naturally infected with SARSCoV-2; therefore, experimental manipulations
aimed at either virus adaptation or at inducing
exogenous expression of the human ACE2 receptor
are required. However, the induction of human
ACE2 expression has yielded inconsistent ﬁndings
with aberrant tissue distribution in different ACE2
transgenic models, making the results difﬁcult to
interpret [4]. In contrast, hamsters are naturally
susceptible to SARS-CoV-2 and, upon infection,
they can develop certain key features of COVID-19
(e.g., pneumonia and release of proinﬂammatory
cytokines) [5e7]. Notably, preclinical research with
hamster models e involving testing of antiviral
drugs, monoclonal antibodies, and vaccines e has
yielded results that were consistent with subsequent
clinical data [8e11].
Perilla (Perilla frutescens) leaves have been
extensively used in folk Asian medicine to rectify
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stomach function, discharge heat, and improve
healthy qi. Additionally, they have enjoyed large
popularity for ethnopharmacological uses in
Europe. Using in vitro experiments, we have previously shown that perilla leaf extract (PLE) exerts
virucidal activity against SARS-CoV-2 in Vero E6
and Calu3 cells e which was noticeably accompanied by an immunomodulatory effect [12]. A synergistic antiviral activity when PLE was combined
with remdesivir was also observed. In this study,
we expanded our prior research and tested whether
PLE can exert in vivo anti-SARS-CoV-2 activity in
the hamster animal model. Because clinical manifestations of the disease in animals are frequently
subtle and difﬁcult to chart without resorting to
pathological examinations, we also assessed
whether serum biomarker-guided disease monitoring may foster our ability to investigate the effects of compounds with purported anti-SARSCoV-2 activity e including PLE.

2. Materials and methods
2.1. Cell cultures and viral infections
African green monkey kidney epithelial cells
(Vero E6) were obtained from ATCC (Manassas, VA,
USA) and maintained in Dulbecco's modiﬁed Eagle
medium (DMEM; Gibco; Gaithersburg, MD, USA)
supplemented with 10% (w/v) fetal bovine serum
(FBS). The prototype SARS-CoV-2 strain CGU4
(Taiwan/CGMH-CGU-01/2020; GISAID identiﬁer:
EPI_ISL_411915;
NCBI
accession
number:
MT192759) was kindly provided by the Taiwan CDC
and propagated in Vero E6 cells [12]. Sanger
sequencing was used to conﬁrm the genomic
sequence. All SARS-CoV-2 experiments were carried out in either biosafety level (BSL)-3 or 4
certiﬁed laboratories.
2.2. Ethical statement
All animal procedures complied with the ARRIVE
guidelines (www.arriveguidelines/org/) and were
reviewed and approved by the National Defense
Medical Center Animal Care and Use Committee
(approval numbers: AN-109-02 and AN-109-41).
2.3. Syrian hamster experiments
The hamster model of SARS-CoV-2 infection has
been previously described in detail [6,7]. Brieﬂy,
Syrian hamsters were purchased from the National Laboratory Animal Center (Taipei, Taiwan)
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Fig. 1. PLE alleviates SARS-CoV-2-induced body weight loss and viral protein expression in hamsters which had undergone a high-dose SARS-CoV2 challenge. (A) Summary of the experimental design. Hamsters were intranasally infected with SARS-CoV-2 (5.73  105 pfu). Each animal in the
low-dose group (LDV) received 80 mg PLE/kg/day in drinking water from the day before infection (1 dpi) until 6 dpi. The high-dose group (HDV)
received a single intraperitoneal daily dose of PLE (90 mg/kg/day) as well as oral PLE (80 mg/kg/day) in drinking water, totaling 170
(90 mg þ 80 mg) mg/kg/day. Animals (n ¼ 3 per group) were euthanized on day 3 or day 6 and jugular blood was collected for biochemical analyses.
(B) Changes in body weight following SARS-CoV-2 infection were recorded on a daily basis; the body weight measured on the day of infection was
arbitrarily set to 1. (C) Western blot analysis of NP protein expression in lung tissues collected at 3 dpi. Lysates obtained from lobe 2 were prepared in
RIPA buffer and subjected to 8% SDS-PAGE (quantity of lysate per lane: 50 mg) using speciﬁc antibodies raised against NP and GAPDH. The
intensity of the NP protein bands was quantiﬁed after normalization to GAPDH expression. (D) At 3 and 6 dpi, immunohistochemistry was applied to
investigate NP expression levels in lung tissues of hamsters treated with PLE. The ratio of positive NP expression e calculated as the number of NPpositive cells divided by the total number of cells e was analyzed using an Aperio Imagescope v12.3. (BeC) Data are expressed as means ± standard
errors of the mean. Statistical signiﬁcance was determined by a two-tailed Student's t-test. ns, not signiﬁcant; **p < 0.01.
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and fed a standard low-fat polysaccharide-rich
chow diet (LabDiet 5053; Purina, St Louis, MO,
USA). Intranasal inoculation of SARS-CoV-2
(strain CGU4) was performed under anesthesia
(Zoletil® 40 mg/kg plus xylazine 4 mg/kg). The
antiviral activity of PLE was assessed through the
following parameters: daily changes in body
weight, serum biochemistry, histopathology,
immunopathology, and virus quantiﬁcation in the
lungs. Lung lobe #2 was used for qPCR, western
blotting, and titer determination, whereas histopathology was carried out on lobe #5. A high-dose
SARS-CoV-2 challenge was applied to mimic severe disease in humans (Fig. 1A). To this aim, 8-9week-old hamsters were intranasally infected (0
day postinfection [dpi]) with SARS-CoV-2
(5.73  105 plaque-forming units [pfu] in 50 mL
PBS). Two different PLE doses (low versus high
dose) were administered from the day before
infection (1 dpi) until 6 dpi. Each hamster in the
low-dose group (LDV) received 80 mg PLE/kg/day
in drinking water e based on a reported daily
consumption of 10 mL drinking water per animal
[13] e ad libitum and refreshed on day 3. The highdose group (HDV) received a single intraperitoneal daily dose of PLE (90 mg/kg/day) as well as
oral PLE (80 mg/kg/day) in drinking water,
totaling 170 (90 mg þ 80 mg) mg/kg/day. The
amount of PLE delivered to hamsters was calculated based on an EC50 value of 0.125 mg/mL
derived from cell-based assays [12]. Because each
hamster weighed ~100 g and had a total blood
volume of 8 mL, animals in the LDV and HDV
arms received 8  EC50 (80 mg/kg/day) and
17  EC50 (170 mg/kg/day) of PLE, respectively.
Hamsters were euthanized on day 3 or day 6 by
Zoletil® overdosing, and lung and jugular blood
samples were collected for analyses. In separated
experiments, a low-dose SARS-CoV-2 challenge
(350 pfu in 50 mL PBS) was applied to mimic mild
disease in humans. Two different PLE preparations obtained as previously described [12] were
given to experimental hamsters. PLE (2.5  EC50)
and its enriched fraction were administered at a
dose of 12.5 mg/kg/day b.i.d. (time interval: 12 h)
for four consecutive days. Animals were sacriﬁced
for sample collection at 4 dpi (Fig. 3A).
2.4. Sample preparation for plaque assay and
western blotting
Lung tissues were homogenized in DMEM using
the bead-beating technology (Precellys Lysing kits;

Bertin Technologies, Aix-en-Provence, France).
Following centrifugation, supernatants were stored
in small aliquots. Viral titers were determined using
a plaque assay following a previously described
methodology [12]. For western analysis, thawed
supernatants were mixed with equal amounts of
RIPA buffer containing lysozyme and proteinase
inhibitors. The protein content was measured with a
protein assay kit (Bio-Rad, Richmond, CA, USA).
Equal amounts of cellular proteins were separated
by SDS-PAGE and subsequently transferred onto
polyvinylidene ﬂuoride membranes. Subsequently,
the membranes were immunoblotted with speciﬁc
primary antibodies and subsequently exposed to
horseradish peroxidase (HRP)-conjugated secondary antibodies. The Immobilon Western HRP
Chemiluminescence Substrate (Millipore, Burlington, MA, USA) was used for blot development.
Mouse monoclonal anti-nucleocapsid (GTX632269,
1:2000 dilution) and anti-GAPDH (GTX627408,
1:5000 dilution) antibodies were obtained from
Genetex (Hsinchu, Taiwan).
2.5. RNA extraction and qRT-PCR analysis
Lung tissues were stored overnight in RNAlater
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) at
4  C, homogenized using the bead-beating technology, and total RNA was subsequently extracted using the TRIzol reagent (Thermo Fisher
Scientiﬁc) according to the manufacturer's instructions. After removal of genomic DNA with
DNase (Promega, Madison, WI, USA), RNA
samples were extracted with the phenol/chloroform method followed by ethanol precipitation.
Equal amounts of total extracted RNA were subsequently reverse transcribed with the M-MLV
reverse transcriptase system (Thermo Fisher Scientiﬁc) using random primers. Subsequently,
qRT-PCR was performed on a QuantStudio3 RTqPCR system (Applied Biosystems, Foster City,
CA, USA) using the following primers speciﬁc for
the E gene: forward 50 -ACA GGT ACG TTA ATA
GTT AAT AGC GT-30 and reverse 50 -ATA TTG
CAG TAC GCA CAC A-3’. The primers for
hamster beta-actin, which served as internal
control, were as follows: forward 50 -ACTG CCG
CAT CCT CTT CCT-30 and reverse 50 -TCG TTG
CCA ATG GTG ATG AC-30 , whereas the
sequence of the SARS-CoV2 E gene probe was 5’[6FAM]ACA CTA GCC ATC CTT ACT GCG CTT
CG[BHQ1]-3’. The relative mRNA expression was
calculated with the 2△Ct method.
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Fig. 2. PLE attenuates SARS-CoV-2-induced immune cell inﬁltrates and alterations in serum biochemical markers. (A) Lung tissues from hamsters
subjected to a high-dose SARS-CoV-2 challenge were collected at 3 dpi (a) and 6 dpi (b). Immunohistochemistry was applied to investigate the
expression rates of the proteins of interest using an Aperio Imagescope v12.3. (B) Biochemical analyses of serum samples collected from jugular veins
were performed on an autoanalyzer. Data are expressed as means ± standard errors of the mean. Statistical signiﬁcance was determined by a twotailed Student's t-test. *p < 0.05, **p < 0.01, and ***p < 0.005.
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2.6. Lung tissue immunohistochemistry
Lung tissue immunohistochemistry (IHC) was
performed by an independent company (BioTools

Co., Ltd; New Taipei City, Taiwan). Brieﬂy, antigen
retrieval was carried out by incubating tissues for
20 min in citrate buffer followed by bovine serum
albumin (BSA) blocking. Primary antibodies raised
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Fig. 3. Virology analysis of hamsters which had undergone a low-dose SARS-CoV-2 challenge. (A) Summary of the experimental design. Hamsters
were intranasally infected with SARS-CoV-2 (350 pfu) and received oral PLE at a dose of 12.5 mg/kg b.i.d. in two different forms, i.e., 1) the original
perilla water extract (ODV) and 2) the partially puriﬁed active (enriched) fraction (EDV). PLE was given at 12 and 2 h before infection as well as in
the post-infection period (starting at 12 h from the intranasal challenge). Oral gavage was continued every 12 h for 4 consecutive days. Animals
(n ¼ 4 per group) were euthanized on day 4. Lung samples were homogenized for western blotting (B), qRT-PCR (C), and plague assay (D) analyses.
Viral protein (NP) and RNA expression levels were normalized to internal controls (GAPDH and a virus control arbitrarily set to 1; BeC). Viral titers
were determined using Vero E6 cells (D). (E) Immunohistochemistry revealed a signiﬁcant reduction of NP expression in PLE-treated animals. The
number of NP-positive cells identiﬁed on lung sections was normalized to the total number of cells using an Aperio Imagescope v12.3. Data are
expressed as means ± standard errors of the mean. Statistical signiﬁcance was determined by a one-tailed Student's t-test. *p < 0.05 and ***p < 0.005.

against SARS-CoV-2 nucleoprotein (NP; Genetex;
product number: GTX135357; 1:200 dilution),
ionized calcium-binding adaptor protein-1 (Iba-1;
Genetex; 1:100 dilution), Ki-67 (Santa Cruz
Biotechnology, Dallas, TX, USA; product number:
sc-23900; 1:50 dilution), myeloperoxidase (MPO;
Santa Cruz Biotechnology; product number: sc365436; 1:50 dilution), Mx1 (Santa Cruz Biotechnology; product number: sc50509; 1:50 dilution) or
anti-CD3 (Ventana Medical Systems, Tucson, AZ,
USA; product number: 790-4341) were applied for
32 min using the automated Ventana Benchmark XT
platform (Ventana Medical Systems). Labeling was
carried out with the Ultraview DAB Detection Kit
(Ventana Medical Systems) according to the manufacturer's protocol. All IHC-stained sections were
counterstained with hematoxylin and eosin (H&E)
using the Ventana reagent, scanned with Aperio
ScanScope CS2 (Leica Biosystems, Buffalo Grove,
IL, USA), and analyzed with an Aperio Imagescope
v12.3 (Leica Biosystems). Default parameters of the
Positive Pixel Count (hue ¼ 0.1; width ¼ 0.5) were
used for antigen detection.

point scale, as follows: 0, absent; 1, minimal (<1%);
2, mild (1e25%); 3, moderate (26e50%); 4, moderately severe (51e75%), and 5, severe (76e100%).
2.8. Serum biochemistry
Biochemical analyses of serum samples collected
from the jugular veins were performed by the National Applied Research Laboratories (Taipei,
Taiwan) on an autoanalyzer (Hitachi 7080; Hitachi
Tokyo, Japan). The following panels were assayed:
1) liver function (aspartate aminotransferase [AST],
alanine aminotransferase [ALT], g-glutamyl transferase [g-GT], albumin [ALB], total bilirubin [T-BIL],
alkaline phosphatase [ALP], total protein [TP]); 2)
renal function (creatinine [CREA], blood urea nitrogen [BUN]); 3) lipid metabolism (high-density
lipoprotein cholesterol [HDL-CHO], low-density lipoprotein cholesterol [LDL], total cholesterol [TCHO], triglycerides [TG]); 4) electrolytes: magnesium [Mg], calcium [Ca], phosphorus [P]); and 5)
glucose and other metabolic parameters (glucose
[GLU], creatine phosphokinase [CPK], uric acid
[UA], lactate dehydrogenase [LDH]).

2.7. Lung pathology
2.9. Statistical analysis
All lung pathology assessments of H&E-stained
sections were independently conducted by two
board-certiﬁed veterinary pathologists (Kan-Hung
Lee and Tzu-Yu Chen; National Applied Research
Laboratories, Taipei, Taiwan). The following histological lesions were systematically assessed: 1)
presence of mixed-cellular inﬂammation, peribronchial, and perivascular inﬁltration; 2) presence of
bronchial epithelial cell degeneration/necrosis e
either with or without bronchiolar inﬂammatory
inﬁltration; 3) presence of alveolar wall necrosis; 4)
presence of vasculitis; 5) presence of hemorrhage
and edema in the pulmonary parenchyma or subpleural areas; and 6) presence of edema in the
alveoli and perivascular areas. The degree of lung
inﬂammation (lesion #1) was graded on a four-point
scale, as follows: 0, absent; 1, mild (<30%); 2, moderate (30e70%), and 3, severe (>70%). Lesions #2e6
were graded as previously described [14] on a six-

Continuous data are expressed as means ±
standard errors of the mean and comparisons were
performed with two-tailed Student's t-test (Figs. 1
and 2; Supplementary Fig. S2). A one-tailed Student's t-test was subsequently used to test differences between PLE-treated and mock-infected
control (virus control [VC]) group; Figs. 3e5).
p values < 0.05 were considered to reﬂect statistically signiﬁcant differences.

3. Results
3.1. PLE attenuates body weight loss and reduces
viral protein expression in hamsters exposed to a
high-dose SARS-CoV-2 challenge
We have previously shown that PLE exerts an in
vitro virucidal activity against SARS-CoV-2 in Vero
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Fig. 4. PLE attenuates SARS-CoV-2-induced lung injury in hamsters which had undergone a low-dose SARS-CoV-2 challenge. Histological
assessment (H&E staining) of lung tissues collected at 4 dpi from hamsters in the VC, ODV, and EDV groups. Left panels: 12.5  magniﬁcation; right
panels of boxed areas: 200  magniﬁcation. (A) Histological appearance of pulmonary lesions. (row a: VC group) Left panel: expansive pulmonary
inﬂammation and alveolar hemorrhage (*). Right panel: mixed interstitial inﬂammatory inﬁltrates (*), vasculitis (arrows), and alveolar necrosis/
hemorrhage. (row b: ODV group) Left panel: multifocal pulmonary inﬂammation (arrows) and presence of free blood within the alveoli (*). Right
panel: mixed interstitial inﬂammatory inﬁltrates (arrows); (row C: EDV group). Left panel: multifocal pulmonary inﬂammation (arrows). Right
panel: mixed interstitial inﬂammatory inﬁltrates, vasculitis (arrow), and alveolar edema (*). (B) The severity of inﬂammatory lesions was graded on a
four-point scale ranging from 0 (no inﬂammation) to 3 (severe inﬂammation) (panel a). The severity of all other lesions was graded on a six-point
scale ranging from 0 to 5. Panel g shows the sum of the lesion scores presented in panels aef. Data are expressed as means ± standard errors of the
mean. Statistical signiﬁcance was determined by a one-tailed Student's t-test. *p < 0.05 and **p < 0.001.

E6 cells [22]. To test whether the same anti-SARSCoV-2 effect could be elicited in vivo, hamsters underwent a high-dose intranasal SARS-CoV-2 challenge (strain CGU4, 5.73  105 pfu) one day after
oral PLE administration e either with or without a
concomitant intraperitoneal injection (Fig. 1A). Two
different PLE dosages were tested and three hamsters in each dose group were sacriﬁced at 3 and 6

dpi. On the day before infection, the LDV group
received PLE in drinking water (80 mg/kg/day per
hamster) to mimic oral PLE uptake. In addition to
PLE in drinking water, the HDV group received a
single daily intraperitoneal PLE injection (90 mg/kg/
day). Hamsters in the negative control (NC) group
did not receive PLE and were not experimentally
infected with SARS-CoV-2. While animals in the NC
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Fig. 4. (Continued)

group gained weight over a 6-day interval, hamsters
in the VC group experienced weight loss after
SARS-CoV-2 infection (Fig. 1B) [5e7]. Similar to the
VC groups, animals in the HDV group started losing
weight from 1 dpi. However, differently from the

former, a gradual recovery was evident from 3 to 6
dpi in the latter group (Fig. 1B). No protection
against weight loss was observed in the LDV group.
Compared with the VC group at 3 dpi, animals in
the HDV group e but not those in the LDV group e
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Fig. 5. PLE attenuates SARS-CoV-2-induced immune cell inﬁltration in hamsters which had undergone a low-dose SARS-CoV-2 challenge.
Immunohistochemistry was applied to investigate the lung tissue expression of Iba-1, MPO, Ki-67, CD3, and Mx1. The number of antigen-positive
cells identiﬁed on lung sections was normalized to the total number of cells using an Aperio Imagescope v12.3. Data are expressed as means ±
standard errors of the mean. Statistical signiﬁcance was determined by a one-tailed Student's t-test. *p < 0.05.

showed a lower level of NP expression in the lung
(Fig. 1C). At 6 dpi, the amount of NP expression in
all groups was below the limit of detection of
western blotting (data not shown).
Immunohistochemistry carried out at 3 dpi
revealed that e differently from the NC group e
animals in the VC group showed an abundant
expression of NP in lung tissues. However, NP
expression levels declined signiﬁcantly at 6 dpi e a
ﬁnding in accordance with previous observations
[1,5,7] on peak viral replication occurring at ~3 dpi,
followed by a steep decline at barely detectable
levels (Fig. 1D). A quantitative analysis of NP
expression levels revealed a signiﬁcantly higher
abundance (p < 0.05) in the VC group compared
with the NC group at 3 dpi (positivity: ~60%);
however, positivity rates markedly decrease to ~25%
at 6 dpi (bottom panels, Fig. 1D). At 3 dpi and
compared with the VC group, the number of NPpositive cells did not differ signiﬁcantly in the LDV
and HDV groups. However, PLE promoted a

substantial dose-dependent inhibition of NP
expression at 6 dpi (bottom panels, Fig. 1D).
Collectively, these data indicate that PLE e at the
dose applied in the HDV group e tends to downregulate the lung cellular expression of the NP viral
protein, although not signiﬁcantly so (Fig. 1C and
D).
3.2. PLE attenuates inﬂammation and reduced
alterations in serum biomarkers in hamsters
exposed to a high-dose SARS-CoV-2 challenge
The severity of SARS-CoV-2-induced pneumonia
was paralleled by an increased expression of immune cell markers e including Iba-1-positive macrophages, CD3-positive T lymphocytes, and MPOpositive neutrophils (Fig. 2A; Fig. S1). Immunohistochemical expression of both Iba-1 and Mx1 was
signiﬁcantly higher in the VC group compared with
the NC group; a similar e albeit not signiﬁcant e
trend was observed for MPO and CD3 (panel a;
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Fig. 6. PLE attenuates SARS-CoV-2-induced lung injury and biochemical alterations in the hamster model: summary of the main ﬁndings.
Experimental infection with SARS-CoV-2 elicited an inﬂammatory response in lung tissues as reﬂected by an increased number of Iba-1-positive
macrophages and MPO-positive neutrophils. A higher number of cells expressing Mx1 and the proliferation marker Ki-67 was also evident. However,
no alterations in the number of CD3-positive T cells were observed. Treatment with PLE reduced SARS-CoV-2-induced lung injury and alterations in
biochemical markers. In addition, we found a signiﬁcant inhibition of viral replication, as reﬂected by a reduced NP expression.

Fig. 2A). In addition, SARS-CoV-2 infection induced
cell proliferation as attested by an increased
expression of Ki-67 (panel a; Fig. 2A). Interestingly,
these immunohistochemical ﬁndings were attenuated by treatment in LDV and/or HDV groups, the
only exception being CD3-positive T lymphocytes at
3 and 6 dpi (panels a and b, Fig. 2A and Fig. S1).
Collectively, these data indicate that PLE attenuates
SARS-CoV-2-induced lung inﬂammation by exerting a signiﬁcant immunomodulatory activity
(Fig. 2A and Fig. S1) [12]. The severity of COVID-19
has been associated with alterations in serum biomarkers e including AST, ALT, g-GT, BUN, HDLCHO, and T-CHO [15e18]. At 3 dpi, we found that e
compared with the VC group e both the HDV and
LDV groups showed less marked increases in serum
AST, ALT, g-GT, and BUN levels, whereas no effect
on CREA was observed (Fig. 2B and Fig. S2). On the
one hand, these results suggest that PLE does not
cause hepatic or renal toxicity; on the other hand,
they also indicate that it can exert hepatoprotective
effects in SARS-CoV-2-infected hamsters [19,20].
Interestingly, serum levels of HDL-CHO and TCHO were reduced following SARS-CoV-2 infection
e possibly as a consequence of virus-induced hepatic damage. Both of these effects were attenuated
by PLE (panel c; Fig. 2B).

3.3. PLE is more effective in hamsters exposed to a
low-dose SARS-CoV-2 challenge
To mimic a mild human infection and to test the
potential effectiveness of oral PLE, hamsters underwent a low-dose intranasal SARS-CoV-2 challenge (350 pfu; 100 ID50) following a procedure
similar to that implemented for the testing of the
orally bioavailable prodrug molnupiravir (MK4482) in hamsters [10]. To this aim, animals
received oral PLE at a dose of 12.5 mg/kg b.i.d.
(~2.5  EC50, Fig. 3A) in two different forms, i.e., 1)
the original perilla water extract (ODV) and 2) the
partially puriﬁed active (enriched) fraction (EDV).
The latter had a 2-fold higher anti-SARS-CoV-2
activity in Vero E6 cells compared with the former
(data not shown). Following sacriﬁce at 4 dpi,
Western blot analysis revealed that EDV inhibited
lung NP expression more effectively than ODV
(Fig. 3B). Both EDV and ODV groups showed
suppression of viral RNA expression and viral titers
based on the results of qPCR and plaque assay,
respectively (Fig. 3C-D). Additionally, IHC
revealed that hamsters in the VC group had a
markedly high lung NP expression e which was
signiﬁcantly attenuated in the EDV and ODV
groups (Fig. 3E).

On examining H&E-stained lung tissues harvested at 4 dpi, hamsters in the VC group showed
mixed alveolar, interstitial, peribronchial, and perivascular inﬂammatory inﬁltrates consisting of neutrophils, lymphocytes, and histiocytes (row a,
Fig. 4A). Vasculitis in VC animals was characterized
by ﬁbrinoid degeneration and inﬁltration by neutrophils and lymphocytes (arrows; Fig. 4A).
Compared with the VC group, hamsters in the ODV
and EDV groups were characterized by less severe
inﬂammatory damage and lower amounts of alveolar and perivascular hemorrhage and edema
(Fig. 4A and analysis in panels aec of Fig. 4B).
However, the lowest degrees of hemorrhage,
edema, vasculitis, epithelial degeneration, and
alveolar wall necrosis were observed in the EDV
group (panels aef, Fig. 4B) as shown by the sum of
histological scores (panel g, Fig. 4B). We subsequently applied IHC to investigate the expression of
inﬂammatory markers in lung tissues (Fig. 5;
Fig. S3). The results consistently revealed reduced
expression levels of Iba-1, MPO, and Ki-67 in the
ODV group and, more markedly, in the EDV group
(Fig. 4). Collectively, these results indicate that PLE
inhibits SARS-CoV-2-induced inﬂammation (panels
aec, Fig. 5). However, treatment with PLE did not
appreciably change both CD3-positive T cells
(Fig. 2A; panel d, Fig. 5) and the expression of the
interferon-inducible gene Mx1 e although a transient increase of these variables was observed during the course of the experiment (panel e, Fig. 5).

4. Discussion
An orally available antiviral drug with preventive
and therapeutic potential is expected to enrich our
armamentarium in the battle against the ongoing
COVID-19 pandemic. We have previously demonstrated that PLE e an orally deliverable traditional
Chinese medicine approved by the Taiwan Food and
Drug Administration e not only inhibits SARS-CoV2 by directly targeting the virions but also hampers
the exaggerated cytokine response in Calu-3 cells
[12]. In this proof-of-concept animal study, we
investigated whether the hamster may represent a
suitable model for human COVID-19 and investigated whether PLE may exert an in vivo immunomodulatory and therapeutic activity. The summary
of our main ﬁndings is shown in Fig. 6: PLE
attenuates SARS-CoV-2-induced lung injury and
biochemical alterations in the hamster model.
Hamsters are known to express the ACE2 receptor
[1,6,10] and e following SARS-CoV-2 infection e
may develop symptoms resembling those of human
COVID-19 [5,7,21]. In addition, and similarly to the
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human receptor, hamster ACE2 has higher afﬁnity
for SARS-CoV-2 than SARS-CoV-1 [21]. Previous
research has focused on the hamster as an animal
platform for vaccine development and the testing of
antiviral agents against SARS-CoV-2 [8e11]. In the
current study, we demonstrated that infected Syrian
hamsters develop mixed alveolar, interstitial, peribronchial, and perivascular inﬂammatory inﬁltrates
(Fig. 4A) e a ﬁnding in agreement with previous
observations from patients with COVID-19 [22e24].
Other lesions similar to those reported in humans
include alveolar wall necrosis, vasculitis, as well as
hemorrhage and edema of the alveoli and perivascular areas (Fig. 4). Interestingly, we found that
orally delivered PLE attenuated the severity of these
alterations in our experimental model e especially
when the enriched fraction was administered (Fig. 4).
Collectively, these data indicate that the hamster
model is suitable to shed light on the mechanistic
underpinnings of novel anti-SARS-CoV-2 drugs.
Liver biochemical abnormalities have been
extensively documented in patients with COVID-19
e especially in presence of severe disease [25e27].
Notably, hepatotoxicity has also been reported in
COVID-19 patients who had been treated with
remdesivir or lopinavir-ritonavir [25,28]. Another
study demonstrated that patients with COVID-19
patients without pre-existing liver disease who
required intensive care had more severe virusinduced liver damage than those who did not [29].
Additionally, more pronounced increases in AST
and ALT have been reported in severe COVID-19
compared with mild disease [15,16,30]. Interestingly,
there is also evidence that SARS-CoV-2 can exert
direct hepatotoxic damage [27].
Another notable ﬁnding from our study is that
SARS-CoV-2-infected hamsters displayed increased
BUN and lower levels of HDL-CHO and T-CHO
(Fig. 2B) e a ﬁnding in accordance with published
clinical studies in patients with COVID-19 [17,18].
While both HDL-CHO and T-CHO may play a role
in SARS-CoV-2 entry into host cells [31,32], their
levels tend to decrease over the course of infection
either because of their consumption during viral
invasion [18] or virus-induced hepatocyte dysfunction that impairs normal lipid metabolism. As for
renal function, an increased BUN e which may
result from renal damage related to virus-induced
aberrant release of proinﬂammatory cytokines e
has been identiﬁed as being an adverse prognostic
factor in terms of in-hospital mortality [17,33]. This
is, to our knowledge, the ﬁrst animal study to
investigate the biochemical indices of liver (AST,
ALT, g-GT) and renal (BUN) function in hamsters
experimentally
infected
with
SARS-CoV-2.

ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:252e270

266

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:252e270

ORIGINAL ARTICLE

Alterations in these biochemical markers might not
only reﬂect the direct pathogenic effects of the virus
but also the potential hepatic and renal toxicities of
antiviral drugs. In this scenario, the combined
monitoring of body weight changes and alterations
in biochemical markers following SARS-CoV-2
infection may allow conducting more humane
research in the hamster model, without resorting to
animal sacriﬁce.
PLE has a multifaceted therapeutic potential that
includes anti-oxidant properties [34,35]. Interestingly, a previous study in a rodent model demonstrated that PLE can alleviate hydroperoxideinduced oxidative hepatotoxicity e suggesting that
the extract may protect the liver against druginduced damage [20]. On analyzing the results of
cell-based assays, we have previously shown that
PLE and remdesivir may exert synergistic therapeutic effects [12]; however, remdesivir has the
potential to induce liver injury [25,28]. An interesting implication of our data is that PLE, given in
combination with other anti-SARS-CoV-2 drugs,
might not only show pharmacological synergy but
also concomitantly reduce the risk of drug-induced
hepatotoxicity.
PLE may also have prophylactic applications
against COVID-19 based on its virucidal activity
against virus particles [16]. In the current study, we
found that PLE-mediated inhibition of NP expression in hamster lung tissues was more pronounced
following a low-dose SARS-CoV-2 challenge (Figs.
3e5). Consequently, the oral administration of PLE
may be a viable strategy both for preventing SARSCoV-2 infections and for tackling the disease at an
early stage. Additionally, PLE appears to be welltolerated and is “Generally Recognized as Safe”
(GRAS) by the Taiwan FDA [36]. In this scenario,
PLE may have applications in the risk management
of the COVID-19 pandemic during the progressive
reopening of international ﬂights. For example,
PLE may be given on arrival spots in destinations
where quarantine is mandatory before entering a
country. Other potential applications of oral PLE
may include disease prevention in COVID-19 patients’ households and out-of-hospital treatment of
mild or asymptomatic cases. Pending conﬁrmation
in phase 3 clinical trials, the use of PLE may have
important public health implications during
the ongoing pandemic, especially in low-income
countries where antibody cocktail treatments might
not be invariably affordable.

5. Conclusions
Our current data indicate that the Syrian hamster
is a suitable animal model that recapitulates the
main features of human COVID-19 e both in terms
of lung pathology and alterations of biological
markers. Collectively, our ﬁndings suggest that this
animal platform may have valuable applications for
testing novel herbal medicines against SARS-CoV-2
infection. Finally, our results expand prior research
by conﬁrming that PLE may exert an in vivo
immunomodulatory and therapeutic activity.
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Appendix

Fig. S1. PLE attenuates SARS-CoV-2-induced immune cell inﬁltrates in the lung. Lung tissues from hamsters were exposed to different doses of PLE
following SARS-CoV-2 challenges. Cells were subsequently collected at 3 and 6 dpi and stained with different immune cell markers. Immunohistochemical images were subsequently analyzed to assess immune cell inﬁltration (Fig. 2A).
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Fig. S2. PLE attenuates SARS-CoV-2-induced changes in serum biochemical markers. Serum samples were collected from hamsters treated with
different doses of PLE and experimentally exposed to SARS-CoV-2. Different biochemical markers of virus-induced organ damage were quantiﬁed.
Data are grouped according to the biomarker function and presented as dot charts (Fig. 2B and Fig. S2).
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Fig. S2. (Continued)

Fig. S3. PLE attenuates SARS-CoV-2-induced immune cell inﬁltration in hamsters experimentally exposed to a low-dose SARS-CoV-2 challenge.
Lung tissues were subsequently collected and stained with different immune cell markers. Immunohistochemical images were subsequently analyzed
to assess immune cell inﬁltration (Fig. 5).
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